EGF receptor (EGFR)-targeted monoclonal antibodies are effective in a subset of metastatic colorectal cancers. Inevitably, all patients develop resistance, which occurs through emergence of KRAS mutations in approximately 50% of the cases. We show that amplification of the MET proto-oncogene is associated with acquired resistance in tumors that do not develop KRAS mutations during anti-EGFR therapy. Amplification of the MET locus was present in circulating tumor DNA before relapse was clinically evident. Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors. These results highlight the role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer and encourage the use of MET inhibitors in patients displaying resistance as a result of MET amplification.

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer.

BARDELLI, Alberto;CORSO, Simona;BERTOTTI, Andrea;SIRAVEGNA, GIULIA;SCALA, Elisa;ZECCHIN, Davide;APICELLA, MARIA;MIGLIARDI, GIORGIA;GALIMI, Francesco;COMOGLIO, Paolo;TRUSOLINO, Livio;DI NICOLANTONIO, Federica;GIORDANO, Silvia;
2013

Abstract

EGF receptor (EGFR)-targeted monoclonal antibodies are effective in a subset of metastatic colorectal cancers. Inevitably, all patients develop resistance, which occurs through emergence of KRAS mutations in approximately 50% of the cases. We show that amplification of the MET proto-oncogene is associated with acquired resistance in tumors that do not develop KRAS mutations during anti-EGFR therapy. Amplification of the MET locus was present in circulating tumor DNA before relapse was clinically evident. Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors. These results highlight the role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer and encourage the use of MET inhibitors in patients displaying resistance as a result of MET amplification.
3
6
658
673
http://cancerdiscovery.aacrjournals.org/content/3/6/658.long
GENE COPY NUMBER; ACQUIRED-RESISTANCE; C-MET; TYROSINE KINASE; PHASE-II; AUTOCRINE ACTIVATION; MONOCLONAL-ANTIBODY; LUNG-CANCER; CETUXIMAB; GROWTH
Bardelli A*;Corso S*;Bertotti A*;Hobor S;Valtorta E;Siravegna G;Sartore-Bianchi A;Scala E;Cassingena A;Zecchin D;Apicella M;Migliardi G;Galimi F;Lauricella C;Zanon C;Perera T;Veronese S;Corti G;Amatu A;Gambacorta M;Diaz LA Jr;Sausen M;Velculescu VE;Comoglio P;Trusolino L;Di Nicolantonio F;Giordano S;Siena S (*Co-First Authors)
File in questo prodotto:
File Dimensione Formato  
Bardelli_MET_CancerDiscovery_2013.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.9 MB
Formato Adobe PDF
1.9 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Bardelli et al.pdf

Accesso aperto con embargo fino al 01/06/2014

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.91 MB
Formato Adobe PDF
1.91 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/134432
Citazioni
  • ???jsp.display-item.citation.pmc??? 263
  • Scopus 484
  • ???jsp.display-item.citation.isi??? 472
social impact